NYSE · BRK-B
Berkshire Hathaway Inc.
$541.96+$1.62 (+0.3%)
Berkshire Hathaway Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.45% below the high.
Loading market information…
AMEX · SDEV · USD
Stock price, earnings
Quote as of Oct 29, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Stablecoin Development Corp.’s quoted price sits in the lower half of its reported 52-week range, 89.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Stablecoin Development Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. The company was formerly known as NovaBay Pharmaceuticals, Inc. and changed its name to Stablecoin Development Corporation in April 2026. Stablecoin Development Corporation was incorporated in 2000 and is headquartered in Emeryville, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
| Q1 2025 | Apr 2, 2025 | -$23.45-1,854.17% vs estimate | $2.31M-7.64% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$3.00-96.72% vs estimate | $2.44M-6.12% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$541.96+$1.62 (+0.3%)
Berkshire Hathaway Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.45% below the high.
$343.58+$4.28 (+1.26%)
JPMorgan Chase & Co.’s quoted price sits in the upper half of its reported 52-week range, 6.25% below the high.
$29.99+$0.60 (+2.04%)
Harrow Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.32% below the high.
$8.24+$0.26 (+3.26%)
Oculis Holding AG’s quoted price sits in the lower half of its reported 52-week range, 76.1% below the high.
$10.72-$0.40 (-3.6%)
Turn Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.83% below the high.
$0.74-$0.03 (-4.15%)
Ocugen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.74% below the high.
$68.66+$0.48 (+0.7%)
Sol-Gel Technologies Ltd.’s quoted price sits in the upper half of its reported 52-week range, 29.92% below the high.
$0.38+$0.00 (+0.69%)
EyePoint Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.01% below the high.
